{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:27:58Z","timestamp":1789032478240,"version":"build-2803163510"},"reference-count":60,"publisher":"American Society of Hematology","issue":"14","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect on surviving myeloma cells by analyzing paired MM samples collected at diagnosis and relapse in the IFM 2009 study. We performed deep whole-genome sequencing on samples from 68 patients, 43 of whom were treated with RVD (lenalidomide, bortezomib, and dexamethasone) and 25 with RVD\u00a0+ HDM. Although the number of mutations was similar at diagnosis in both groups (7137 vs 7230; P\u00a0= .67), the HDM group had significantly more mutations at relapse (9242 vs 13\u2009383, P\u00a0= .005). No change in the frequency of copy number alterations or structural variants was observed. The newly acquired mutations were typically associated with DNA damage and double-stranded breaks and were predominantly on the transcribed strand. A machine learning model, using this unique pattern, predicted patients who would receive HDM with high sensitivity, specificity, and positive prediction value. Clonal evolution analysis showed that all patients treated with HDM had clonal selection, whereas a static progression was observed with RVD. A significantly higher percentage of mutations were subclonal in the HDM cohort. Intriguingly, patients treated with HDM who achieved complete remission (CR) had significantly more mutations at relapse yet had similar survival rates as those treated with RVD who achieved CR. This similarity could have been due to HDM relapse samples having significantly more neoantigens. Overall, our study identifies increased genomic changes associated with HDM and provides rationale to further understand clonal complexity.<\/jats:p>","DOI":"10.1182\/blood.2022017094","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T21:06:26Z","timestamp":1672952786000},"page":"1724-1736","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma"],"prefix":"10.1182","volume":"141","author":[{"given":"Mehmet Kemal","family":"Samur","sequence":"first","affiliation":[{"name":"1Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Roncador","sequence":"additional","affiliation":[{"name":"3Zurich University Hospital, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-0562","authenticated-orcid":false,"given":"Anil","family":"Aktas Samur","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Fulciniti","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Hamid","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Szalat","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-6829","authenticated-orcid":false,"given":"Masood A.","family":"Shammas","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":false,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5031-3748","authenticated-orcid":false,"given":"Florence","family":"Magrangeas","sequence":"additional","affiliation":[{"name":"7Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), INSERM, French National Centre for Scientific Research (CNRS), Angers University, and Nantes University, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1389-312X","authenticated-orcid":false,"given":"Stephane","family":"Minvielle","sequence":"additional","affiliation":[{"name":"7Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), INSERM, French National Centre for Scientific Research (CNRS), Angers University, and Nantes University, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"8University Cancer Center of Toulouse Institut National de la Sant\u00e9, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[{"name":"8University Cancer Center of Toulouse Institut National de la Sant\u00e9, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"7Center for Research in Cancerology and Immunology Nantes-Angers (CRCINA), INSERM, French National Centre for Scientific Research (CNRS), Angers University, and Nantes University, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0415-1706","authenticated-orcid":false,"given":"Anjan","family":"Thakurta","sequence":"additional","affiliation":[{"name":"9Bristol Myers Squibb, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8783-5961","authenticated-orcid":false,"given":"Giovanni","family":"Parmigiani","sequence":"additional","affiliation":[{"name":"1Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Biostatistics, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3050-0140","authenticated-orcid":false,"given":"Herv\u00e9","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"8University Cancer Center of Toulouse Institut National de la Sant\u00e9, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston, MA"},{"name":"10VA Boston Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"11","key":"2023110319214665900_bib1","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2023110319214665900_bib2","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1038\/s41375-020-0819-8","article-title":"Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma","volume":"34","author":"Goldschmidt","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2023110319214665900_bib3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/leu.2013.220","article-title":"Association of response endpoints with survival outcomes in multiple myeloma","volume":"28","author":"Lonial","year":"2014","journal-title":"Leukemia"},{"issue":"17","key":"2023110319214665900_bib4","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1002\/cam4.4137","article-title":"Front-line treatment patterns in multiple myeloma: an analysis of U.S.-based electronic health records from 2011 to 2019","volume":"10","author":"Kumar","year":"2021","journal-title":"Cancer Med"},{"issue":"11","key":"2023110319214665900_bib5","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.clml.2020.06.015","article-title":"Perspectives in the rapidly evolving treatment landscape of multiple myeloma: expert review of new data presentations from ASH 2019","volume":"20","author":"Joo","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"2023110319214665900_bib6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023110319214665900_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current treatment strategies for multiple myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"2023110319214665900_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"9","key":"2023110319214665900_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"2023110319214665900_bib10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/EDBK_320105","article-title":"How to treat high-risk myeloma at diagnosis and relapse","volume":"41","author":"Caro","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"2023110319214665900_bib11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.2174\/1871520619666190305141458","article-title":"Nitrogen mustards as alkylating agents: a review on chemistry, mechanism of action and current USFDA status of drugs","volume":"19","author":"More","year":"2019","journal-title":"Anti Cancer Agents Med Chem"},{"issue":"5","key":"2023110319214665900_bib12","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.chembiol.2013.04.007","article-title":"DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology","volume":"20","author":"Cheung-Ong","year":"2013","journal-title":"Chem Biol"},{"issue":"2","key":"2023110319214665900_bib13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"12","author":"Fu","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2023110319214665900_bib14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2019.03.001","article-title":"A\u00a0compendium of mutational signatures of environmental agents","volume":"177","author":"Kucab","year":"2019","journal-title":"Cell"},{"issue":"1","key":"2023110319214665900_bib15","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/s41467-020-15912-7","article-title":"Mutational signatures are jointly shaped by DNA damage and repair","volume":"11","author":"Volkova","year":"2020","journal-title":"Nat Commun"},{"issue":"9","key":"2023110319214665900_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2023110319214665900_bib17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2023110319214665900_bib18","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"2023110319214665900_bib19","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41375-021-01293-3","article-title":"The\u00a0mutagenic impact of melphalan in multiple myeloma","volume":"35","author":"Maura","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"2023110319214665900_bib20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/bloodadvances.2019000779","article-title":"Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma","volume":"4","author":"Ziccheddu","year":"2020","journal-title":"Blood Adv"},{"issue":"27","key":"2023110319214665900_bib21","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.20.00461","article-title":"Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group","volume":"38","author":"Samur","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2023110319214665900_bib22","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2023110319214665900_bib23","doi-asserted-by":"publisher","DOI":"10.1101\/861054","article-title":"Calling somatic SNVs and indels with Mutect2","author":"Benjamin","year":"2  2019","journal-title":"bioRxiv"},{"issue":"16","key":"2023110319214665900_bib24","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"2023110319214665900_bib25","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","article-title":"Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications","volume":"32","author":"Chen","year":"2016","journal-title":"Bioinformatics"},{"issue":"1","key":"2023110319214665900_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl Variant Effect Predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"issue":"5","key":"2023110319214665900_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"Carter","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2023110319214665900_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023110319214665900_bib29","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"2023110319214665900_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-019-0199-3","article-title":"Deciphering the chronology of copy number alterations in Multiple Myeloma","volume":"9","author":"Aktas Samur","year":"2019","journal-title":"Blood Cancer J"},{"issue":"18","key":"2023110319214665900_bib31","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"issue":"1","key":"2023110319214665900_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-018-0539-0","article-title":"MutationalPatterns: comprehensive genome-wide analysis of mutational processes","volume":"10","author":"Blokzijl","year":"2018","journal-title":"Genome Med"},{"issue":"W1","key":"2023110319214665900_bib33","doi-asserted-by":"crossref","first-page":"W39","DOI":"10.1093\/nar\/gkv416","article-title":"The MEME suite","volume":"43","author":"Bailey","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2023110319214665900_bib34","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/bioinformatics\/btr261","article-title":"DREME: motif discovery in transcription factor ChIP-seq data","volume":"27","author":"Bailey","year":"2011","journal-title":"Bioinformatics"},{"issue":"1","key":"2023110319214665900_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/bioinformatics\/btw572","article-title":"signeR: an empirical Bayesian approach to mutational signature discovery","volume":"33","author":"Rosales","year":"2017","journal-title":"Bioinformatics"},{"issue":"11","key":"2023110319214665900_bib36","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1093\/bioinformatics\/btaa895","article-title":"Sigflow: an automated and comprehensive pipeline for cancer genome mutational signature analysis","volume":"37","author":"Wang","year":"2021","journal-title":"Bioinformatics"},{"issue":"7793","key":"2023110319214665900_bib37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"11","key":"2023110319214665900_bib38","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/bioinformatics\/bty016","article-title":"QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction","volume":"34","author":"Deveau","year":"2018","journal-title":"Bioinformatics"},{"issue":"12","key":"2023110319214665900_bib39","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1093\/annonc\/mdx517","article-title":"ClonEvol: clonal ordering and visualization in cancer sequencing","volume":"28","author":"Dang","year":"2017","journal-title":"Ann Oncol"},{"issue":"30","key":"2023110319214665900_bib40","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1073\/pnas.1707945114","article-title":"Fast and accurate HLA typing from short-read next-generation sequence data with xHLA","volume":"114","author":"Xie","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2023110319214665900_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","article-title":"pVACtools: a computational toolkit to identify and visualize cancer neoantigens","volume":"8","author":"Hundal","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2023110319214665900_bib42","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1038\/s41467-019-11037-8","article-title":"A\u00a0practical guide for mutational signature analysis in hematological malignancies","volume":"10","author":"Maura","year":"2019","journal-title":"Nat Commun"},{"issue":"3","key":"2023110319214665900_bib43","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41375-020-0976-9","article-title":"Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age","volume":"35","author":"Mai","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"2023110319214665900_bib44","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023110319214665900_bib45","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"5","key":"2023110319214665900_bib46","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.16764","article-title":"The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?","volume":"191","author":"Kazandjian","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"2023110319214665900_bib47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/CCO.0000000000000783","article-title":"The role of autologous stem-cell transplantation in multiple myeloma in 2021","volume":"33","author":"Mina","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"2023110319214665900_bib48","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3389\/fgene.2019.00861","article-title":"Treatment may be harmful: mechanisms\/prediction\/prevention of drug-induced DNA damage and repair in multiple myeloma","volume":"10","author":"Gourzones","year":"2019","journal-title":"Front Genet"},{"issue":"10","key":"2023110319214665900_bib49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-020-00367-2","article-title":"An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics","volume":"10","author":"Hoang","year":"2020","journal-title":"Blood Cancer J"},{"issue":"11","key":"2023110319214665900_bib50","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3324\/haematol.11435","article-title":"Melphalan-induced DNA damage in\u00a0vitro as a predictor for clinical outcome in multiple myeloma","volume":"92","author":"Dimopoulos","year":"2007","journal-title":"Haematologica"},{"issue":"19","key":"2023110319214665900_bib51","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2005.07.385","article-title":"Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome","volume":"23","author":"Dimopoulos","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2023110319214665900_bib52","doi-asserted-by":"crossref","first-page":"18912","DOI":"10.1038\/s41598-019-55161-3","article-title":"A\u00a0higher throughput assay for quantification of melphalan-induced DNA damage in peripheral blood mononuclear cells","volume":"9","author":"van Kan","year":"2019","journal-title":"Sci Rep"},{"issue":"12","key":"2023110319214665900_bib53","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/ng.3991","article-title":"Reduced mutation rate in exons due to differential mismatch repair","volume":"49","author":"Frigola","year":"2017","journal-title":"Nat Genet"},{"issue":"6","key":"2023110319214665900_bib54","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/cm.21109","article-title":"Myosin 16 levels fluctuate during the cell cycle and are downregulated in response to DNA replication stress","volume":"70","author":"Cameron","year":"2013","journal-title":"Cytoskeleton (Hoboken)"},{"issue":"17","key":"2023110319214665900_bib55","doi-asserted-by":"crossref","first-page":"e150203","DOI":"10.1172\/jci.insight.150203","article-title":"Genomic and epigenomic evolution of acquired resistance to combination therapy in esophageal squamous cell carcinoma","volume":"6","author":"Min","year":"2021","journal-title":"JCI Insight"},{"issue":"1","key":"2023110319214665900_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-020-05586-6","article-title":"The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer","volume":"181","author":"El Ansari","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2023110319214665900_bib57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/bjd.16905","article-title":"Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma","volume":"180","author":"Tina","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"2023110319214665900_bib58","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and\u00a0maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"2023110319214665900_bib59","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2023110319214665900_bib60","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation clearance after transplantation for myelodysplastic syndrome","volume":"379","author":"Duncavage","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/14\/1724\/2087563\/blood_bld-2022-017094-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/14\/1724\/2087563\/blood_bld-2022-017094-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T19:22:52Z","timestamp":1699039372000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/14\/1724\/493962\/High-dose-melphalan-treatment-significantly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":60,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,4,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017094","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}